1 / 34

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice

This program discusses the use of biomarkers in multiple sclerosis (MS) and their role in guiding treatment decisions. It covers topics such as the 2017 McDonald Criteria, CSF oligoclonal bands as prognostic markers, the use of MRI as a biomarker, and the practical advantages of measuring neurofilaments in serum. Real-life evidence and case studies are presented to demonstrate the influence of biomarkers on treatment decision-making.

perdue
Download Presentation

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice

  2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

  3. Introduction

  4. 2017 McDonald Criteria: CSF to Show Dissemination in Time

  5. CSF Oligoclonal Bands as Prognostic Markers

  6. Patient Case 1: Janna

  7. Patient Case 1: Janna (cont)

  8. MRI at Baseline and 6 Months: New Lesions

  9. MRI: Presence of Black Holes

  10. MRI as a Biomarker to Guide Treatment Decision: Clinician's Assessment of the Case

  11. Risk Profiling Biomarkers: Anti-JC Virus Antibody Testing

  12. Neurofilaments: From Detection in CSF to Blood

  13. Practical Advantages of Measuring NfL in Serum

  14. High NfL Levels and Potential Treatment Decision

  15. Low or Continuously High NfL Levels and Potential Treatment Decision

  16. NfL as a Complement to MRI: Summary of Case 1

  17. Real-Life Evidence With NfL in CSF: Influence in Treatment Decision-Making

  18. High NfL Levels and Decision to Initiate Therapy: Czech Republic

  19. High NfL Levels and Decision to Initiate Therapy: Switzerland

  20. High NfL Levels and Decision to Initiate Therapy: United Kingdom

  21. Patient Case 2: Suzanne

  22. Patient Case 2: Suzanne (cont)

  23. Serum NfL Levels as a Predictor of Disease Worsening and Brain and Spinal Cord Atrophy

  24. Practical Use of NfL in the Czech Republic

  25. Hurdles to Overcome in Practical Use of NfL

  26. MRI as a Standardized Biomarker?

  27. Brain Atrophy: Focal Cord and Brain Lesions in RRMS and SPMS

  28. Baseline Tests for Patients Starting on Anti-CD20 Therapy: Infection Screening

  29. Effect of Treatment in Reducing NfL Levels

  30. Concluding Remarks

  31. Concluding Remarks (cont)

  32. Abbreviations

  33. Abbreviations (cont)

More Related